Ipsen S.A. (OTCMKTS:IPSEY) Sees Large Growth in Short Interest

Ipsen S.A. (OTCMKTS:IPSEY) was the recipient of a large growth in short interest in November. As of November 30th, there was short interest totalling 1,700 shares, a growth of 750.0% from the November 15th total of 200 shares. Based on an average daily volume of 2,700 shares, the short-interest ratio is currently 0.6 days.

Analyst Ratings Changes

Separately, Royal Bank of Canada raised shares of Ipsen from a “hold” rating to a “moderate buy” rating in a report on Monday, September 16th.

Ipsen Stock Performance

Shares of OTCMKTS IPSEY traded up $0.95 during mid-day trading on Wednesday, reaching $29.06. The company’s stock had a trading volume of 1,723 shares, compared to its average volume of 1,438. Ipsen has a 52 week low of $27.00 and a 52 week high of $34.06. The stock has a fifty day moving average of $29.94 and a two-hundred day moving average of $30.24.

Ipsen Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.